Gastrointestinal Stromal Tumors. Molecular Markers and Genetic Subtypes

Christine M. Barnett, Christopher Corless, Michael Heinrich

Research output: Contribution to journalArticle

28 Scopus citations


Mutation-activated signaling from the KIT and PDGFRA kinases has been successfully targeted in gastrointestinal stromal tumors (GISTs), with subtle differences between the mutations serving to refine prognosis and more precisely tailor therapy. There is a growing understanding of the molecular drivers of GISTs lacking mutations in KIT or PDGFRA, so called wild-type GISTs, further aiding in management decisions. This article provides an overview of all the known molecular subtypes of GIST and provides information about clinical correlates, treatment, and prognosis depending on the subtype.

Original languageEnglish (US)
Pages (from-to)871-888
Number of pages18
JournalHematology/Oncology Clinics of North America
Issue number5
Publication statusPublished - Oct 2013



  • GIST
  • KIT
  • RTK-wild-type
  • SDH

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this